Skip to main content

Table 1 Characteristics at baseline and follow-up visits of 29 RA patients reporting hand flare during 1 year of follow-up

From: Serial magnetic resonance imaging and ultrasound examinations demonstrate differential inflammatory lesion patterns in soft tissue and bone upon patient-reported flares in rheumatoid arthritis

 Baseline (n = 29)FV1 (flare visit) (n = 29)FV2 (n = 29)FV3 (n = 28)FV4 (n = 28)
No. reporting flare0/2929/2922/293/276/27
Age, years64.8 (9.7)NANANANA
Female/male (%)20/9 (69/31)NANANANA
Disease duration, years10.3 (5.5) [2–21]NANANANA
Anti-CCP positive (%)27 (93)NANANANA
IgM RF positive (%)26 (90)NANANANA
DAS28CRP2.0 (0.7) [1.2–3.1]3.5 (1.0)*** [1.2–5.3]3.0 (1.2)*** [1.2–6.0]2.4 (0.9) [1.2–4.9]2.6 (1.0)* [1.2–4.9]
CRP (mg/l)5.7 (8.6) [0–33]10.1 (12.7)*** [0.4–48]6.8 (9.2) [0–44]6.1 (6.9) [0.4–23]6.8 (11.4) [0.4–56]
SJC280 (0) [0–0]1.5 (1.0)*** [0–4]1.0 (1.4)*** [0–5]0.2 (0.5) [0–2]0.4 (0.7)** [0–3]
TJC280.8 (1.5) [0–7]4.0 (3.5)*** [0–12]3.8 (4.9)*** [0–21]1.6 (2.0) [0–8]1.9 (2.1)** [0–7]
EGA (VAS)4.1 (3.2) [0–11]16.2 (13.1)*** [2–74]11 (9.9)*** [0–47]5.8 (5.8) [0–27]6.5 (5.8) [0–26]
PROs
 Pain (VAS)16.7 (18.4) [0–71]43.2 (22.8)*** [0–74]36.4 (26.7)** [0–98]24.2 (23.7) [0–96]25.8 (22.9) [0–74]
 PGA (VAS)22.1 (23.1) [0–84]43.4 (26.2)*** [0–85]37.1 (26.2)** [0–98]26.3 (24.3) [0–93]26.6 (26.0) [0–80]
 Patient-reported TJC281 (1.9) [0–8]4.0 (3.0)*** [1–11]2.5 (3.5)* [0–14]1.4 (2.6) [0–13]1.8 (2.8) [0–12]
 Patient-reported SJC280 (0) [0–0]2.8 (2.9)*** [1–11]1.9 (3.1)*** [0–12]0.7 (1.8)** [0–8]1 (2.1)** [0–10]
 HAQ0.4 (0.4) [0–1.5]0.6 (0.5)*** [0–1.5]0.5 (0.5) [0–1.8]0.4 (0.5) [0–1.9]0.5 (0.5) [0–1.9]
Patient-reported flare characteristics
 RA-FQ (0–50)10.1 (9.6) [0–33]22.9 (12.7)*** [1–49]15 (10.7) [1–37]9.5 (8.6) [0–35]10.5 (9.9) [0–38]
 Flare severitya (0–10)NA4.8 (2.7) [1–10]2.67 (2.4)*** [0–8]1.25 (2.3)** [0–9]1.45 (2.3)** [0–7]
Flare duration (n)
 1–3 daysNA18414
 4–7 daysNA81000
 8–14 daysNA2000
 > 14 daysNA1422
MRI
 Synovitis10.3 (4.0) [0–17.5]12.7 (3.1)*** [7–19]11.9 (3.2)** [6–19]11.0 (3.7) [3–18.5]11.5 (3.6) [4.5–20]
 Tenosynovitis6.4 (4.7) [0–17.5]9.3 (5.8)*** [1–20.5]8.1 (4.9)** [1–19.5]7.9 (5.2)** [0–20.5]8.2 (4.8)** [0–20.5]
 BME2.6 (4.8) [0–22.5]2.6 (3.1) [0–11]2.9 (3.6)** [0–11.5]2.9 (3.5)** [0–12]2.9 (3.5)* [0–11.5]
 No. (%) with synovitis sum score ≥ 128 (97)29 (100)29 (100)26 (100)26 (100)
 No. (%) with tenosynovitis sum score ≥ 128 (97)29 (100)29 (100)25 (96)26 (100)
 No. (%) with BME ≥ 114 (48)20 (69)18 (62)18 (64)17 (61)
US
 Synovitis (GLOESS)8.3 (5.4) [0–23]11.3 (5.3)* [3–25]10.6 (5.0)* [3–23]9.7 (5.0) [3–23]10.04 (5.1) [3–23]
 Tenosynovitis3.5 (4.6) [0–14]6.3 (6.2)*** [0–19]5.9 (5.9)** [0–24]4.4 (5.0) [0–15]4.6 (5.0) [0–15]
 No.(%) with GLOESS ≥ 128 (97)29 (100)29 (100)28 (100)28 (100)
 No.(%) with tenosynovitis sum score ≥ 118 (62)20 (69)23 (79)19 (68)19 (68)
  1. Mean (SD) [range] or numbers (%) of demographic, clinical, patient-reported, and imaging characteristics. Anti-CCP anti-cyclic citrullinated peptide antibody, BME bone marrow edema, CRP C-reactive protein, DAS disease activity score, EGA evaluator global assessment, FV follow-up visit, GLOESS Global OMERACT (Outcome Measures in Rheumatology) –EULAR European League Against Rheumatism) Synovitis Score, HAQ health assessment questionnaire, MRI magnetic resonance imaging, PGA patient’s global assessment, PROs patient-reported outcomes, RA-FQ OMERACT Rheumatoid Arthritis Flare Questionnaire, RF Rheumatoid factor, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28 joints, US ultrasonography, VAS visual analog scale; p value for paired data comparison between baseline and each follow-up visit assessed by paired t test or Wilcoxon signed-rank test, as appropriate
  2. ***p ≤ 0.001, **p ≤ 0.01, *p < 0.05
  3. aFor variable flare severity comparisons are made vs FV1, as no patient reported flare at baseline
\